MedTrace Logo

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

NCT02672267 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-06

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of human allogeneic ischemia tolerant mesenchymal bone marrow cells (aLoOxMBMC) administered intravenously to subjects with Acute Myocardial Infarction (STEMI, non STEMI).

Conditions

Interventions

BIOLOGICAL

Stem cells

human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant

OTHER

Placebo

Lactated Ringer's Solution

Sponsors & Collaborators

Principal Investigators

  • Saule Abseitova, MD, Prof. · National Research Medical Center

  • Daniyar Jumaniyazov, MD, PhD · Altaco XXI, LLP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672267 on ClinicalTrials.gov